M. Levin

发表

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer

L. Pusztai, B. Leyland-Jones, D. Lipson, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

L. Pusztai, B. Leyland-Jones, D. Lipson, 2017 .

Association of PIK3CA mutation with response (ExRx) to cetuximab (C) in metastatic (met) triple-negative breast cancer (TNBC).

C. Horak, N. Palma, Kai Wang, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.

V. Pascual, J. Banchereau, A. Palucka, 2018, Cancer research.

Frequent MYC coamplification and DNA hypomethylation of multiple genes on 8q in 8p11-p12-amplified breast carcinomas

Toshima Z. Parris, P. Karlsson, K. Helou, 2014, Oncogenesis.

Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer.

J. Rabinowitz, D. V. Von Hoff, V. Espina, 2021, Med.

Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer.

L. Liotta, V. Espina, F. Holmes, 2019, JCO precision oncology.

Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*

Michael L. Gatza, Alissa M. Weaver, C. Perou, 2015, Molecular & Cellular Proteomics.

Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine

R. Yelensky, J. O’Shaughnessy, J. Pippen, 2015, Cancer medicine.

IL 1 Receptor Antagonist Controls Transcriptional Signature of In fl ammation in Patients with Metastatic Breast Cancer

V. Pascual, J. Banchereau, A. Palucka, 2018 .

Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC).

V. Pascual, K. Palucka, J. O’Shaughnessy, 2016 .

Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

V. Zismann, V. Espina, J. O’Shaughnessy, 2023, Biomarker Research.

Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer

J. Rabinowitz, V. Espina, Claudius Mueller, 2021 .

Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts).

K. Palucka, J. O’Shaughnessy, Jennifer L. Smith, 2016 .

Targeting HER2 / HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

M. Pierobon, M. Levin, Esther San Roman Rodriguez, 2024, Cancer reports.